PRPO vs TMO vs A vs PACB

For growth investors, Agilent Technologies, Inc.

(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). Agilent Technologies, Inc. (A) offers the better valuation at 26. 0x trailing P/E (19. 9x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Agilent Technologies, Inc.

(A) is the cheapest at 26. 0x versus Thermo Fisher Scientific Inc. at 26. 8x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 35x versus Thermo Fisher Scientific Inc. 's 9. 05x — a reasonable growth-adjusted valuation.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 8%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: TMO returned +229. 1% versus PRPO's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Precipio, Inc.

(PRPO) is the lower-risk stock at 0. 41β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 491% more volatile than PRPO relative to the S&P 500. On balance sheet safety, Precipio, Inc. (PRPO) carries a lower debt/equity ratio of 10% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agilent Technologies, Inc.

(A) is pulling ahead at 6. 7% versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). On earnings-per-share growth, the picture is similar: Precipio, Inc. grew EPS 35. 0% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, PRPO leads at 21. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agilent Technologies, Inc.

(A) is the more profitable company, earning 18. 8% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 18. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus -348. 5% for PACB. At the gross margin level — before operating expenses — A leads at 52. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 35x versus Thermo Fisher Scientific Inc. 's 9. 05x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 1x forward P/E versus 19. 9x for Agilent Technologies, Inc. — 0. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for A: 39. 9% to $166. 00.

In this comparison, A (0.

8% yield), TMO (0. 4% yield) pay a dividend. PRPO, PACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Precipio, Inc.

(PRPO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41)). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRPO: -98. 9%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

A pays a dividend while PRPO, TMO, PACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.